Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

Susan Kühnast1,2,3†, Sam J.L. van der Tuin3,4†, José W.A. van der Hoorn1,2,3, Jan B. van Klinken3,5, Branko Simic6, Elsbet Pieterman1, Louis M. Havekes1,3,4, Ulf Landmesser7, Thomas F. Lüscher7, Ko Willems van Dijk3,4,5, Patrick C.N. Rensen3,4, J. Wouter Jukema2, and Hans M.G. Princen1*

1Gaubius Laboratory, TNO, Metabolic Health Research, Zernikedreef 9, 2333 CK, PO Box 2215, 2301 CE, Leiden, The Netherlands; 2Department of Cardiology, LUMC, Leiden, The Netherlands; 3Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands; 4Department of Endocrinology and Metabolic Diseases, LUMC, Leiden, The Netherlands; 5Department of Human Genetics, LUMC, Leiden, The Netherlands; 6Center for Molecular Cardiology, Campus Schlieren, University of Zurich, Zurich, Switzerland; and 7University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland

Received 14 February 2014; revised 24 June 2014; accepted 23 July 2014; online publish-ahead-of-print 20 August 2014

Background
The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from atheroprotective HDL to atherogenic (V)LDL. The CETP inhibitor anacetrapib decreases (V)LDL-C by ~15–40% and increases HDL-C by ~40–140% in clinical trials. We evaluated the effects of a broad dose range of anacetrapib on atherosclerosis and HDL function, and examined possible additive/synergistic effects of anacetrapib on top of atorvastatin in APOE*3Leiden.CETP mice.

Methods and results
Mice were fed a diet without or with ascending dosages of anacetrapib (0.03; 0.3; 3; 30 mg/kg/day), atorvastatin (2.4 mg/kg/day) alone or in combination with anacetrapib (0.3 mg/kg/day) for 21 weeks. Anacetrapib dose-dependently reduced CETP activity (−59 to −100%, P < 0.001), thereby decreasing non-HDL-C (−24 to −45%, P < 0.001) and increasing HDL-C (+30 to +86%, P < 0.001). Anacetrapib dose-dependently reduced the atherosclerotic lesion area (−41 to −92%, P < 0.01) and severity, increased plaque stability index and added to the effects of atorvastatin by further decreasing lesion size (−95%, P < 0.001) and severity. Analysis of covariance showed that both anacetrapib (P < 0.05) and non-HDL-C (P < 0.001), but not HDL-C (P = 0.76), independently determined lesion size.

Conclusion
Anacetrapib dose-dependently reduces atherosclerosis, and adds to the anti-atherogenic effects of atorvastatin, which is mainly ascribed to a reduction in non-HDL-C. In addition, anacetrapib improves lesion stability.

Keywords
Cholesteryl ester transfer protein • Non-HDL-cholesterol • HDL-cholesterol • HDL function • Atherosclerosis • Anacetrapib • Atorvastatin
Introduction

Intervention trials provide ample evidence that lowering of low-density lipoprotein-cholesterol (LDL-C) contributes to a reduction in cardiovascular (CV) risk. However, the residual risk that remains after statin treatment, as well as failure for some patients to reach recommended LDL-C targets despite statin treatment, support the addition of other LDL-C-lowering agents and also stimulate the search for secondary treatment targets. Prospective epidemiological studies propose high-density lipoprotein (HDL-C) as a potential target. Cholesterol ester transfer protein (CETP) plays an important role in lipid metabolism by facilitating the transfer of cholesteryl esters from atheroprotective HDL to atherogenic (V)LDL in exchange for triglycerides (TG), and inhibition of CETP activity has been proposed as a therapeutic way to increase HDL-C levels.

In mouse models for atherosclerosis, CETP expression aggravated atherosclerosis development. Most but not all studies in rabbits and mice showed that CETP inhibition reduced atherosclerosis development. However, torcetrapib failed to enhance the antiatherogenic effects of atorvastatin and induced a pro-inflammatory, vulnerable plaque phenotype in APOE*3Leiden.CETP mice. In the large clinical outcome trial (ILLUMINATE), torcetrapib increased the risk of major CV events and mortality despite a 72% increase in LDL-C and a 25% reduction in LDL-C.

The present study is the first intervention study in a well-established, translational mouse model for hyperlipidaemia and atherosclerosis showing that anacetrapib dose-dependently reduces atherosclerosis development and adds to the antiatherogenic effects of atorvastatin. This effect is mainly ascribed to the reduction in non-HDL-C despite a remarkable increase in HDL-C and without affecting HDL functionality. In addition, anacetrapib improves lesion stability.

Translational Perspective

The present study is the first intervention study in a well-established, translational mouse model for hyperlipidaemia and atherosclerosis showing that anacetrapib dose-dependently reduces atherosclerosis development and adds to the anti-atherogenic effects of atorvastatin. This effect is mainly ascribed to the reduction in non-HDL-C despite a remarkable increase in HDL-C and without affecting HDL functionality. In addition, anacetrapib improves lesion stability.

Methods

Animals and diet

Female APOE*3Leiden.CETP transgenic mice were fed a semi-synthetic cholesterol-rich diet for a run-in period of 5 weeks (see Supplementary material online). Animals were matched based on body weight, total cholesterol (TC), TG, HDL-C and age (n = 15 per group) and received a control Western-type diet without or with incremental dosages of anacetrapib (0.03; 0.3; 3; and 30 mg/kg/day; Dalton Chemical Laboratories, Inc., Canada), atorvastatin (2.4 mg/kg/day) or a combination of atorvastatin (2.4 mg/kg/day) and anacetrapib (0.3 mg/kg/day) for a treatment period of 21 weeks. All animals were sacrificed by CO2 inhalation and hearts were isolated to assess atherosclerosis development. Animal experiments were approved by the Institutional Animal Care and Use Committee of The Netherlands Organization for Applied Research (TNO).

Plasma lipids, lipoprotein profile, endogenous cholesteryl ester transfer protein activity, cholesteryl ester transfer protein concentration, serum amyloid A and HDL functionality

Plasma TC, TG, and HDL-C were determined every 2–4 weeks and average TC, TG, and HDL-C levels were calculated by total exposure over number of weeks. To measure HDL-C, apoB-containing particles were precipitated from plasma with 20% polyethylene glycol in 200 mM glycine buffer (pH 10) and cholesterol was measured in the supernatant. The distribution of cholesterol over plasma lipoproteins was determined as previously described.

Plasma endogenous CETP activity and CETP concentration were determined as previously described. Serum amyloid A (SAA; Tridelta development, Co. Kildare, Ireland) was measured by using ELISA according to manufacturer’s instructions.

Cultured arterial endothelial cells were incubated with HDL isolated from control- and anacetrapib-treated mice and pro-inflammatory cytokine-induced vascular cell adhesion molecule 1 (VCAM-1) expression and apoptotic cell death were assessed.

Atherosclerosis quantification

Cross-sections throughout the entire aortic root area were stained to assess atherosclerotic lesion area and severity. The lesions were classified into five categories: (i) early fatty streak, (ii) regular fatty streak, (iii) mild plaque, (iv) moderate plaque, and (v) severe plaque according to the American Heart Association classification and total lesion area, number of lesions, undiseased segments and lesion severity were determined as previously described. Lesion composition of the severe lesions (type IV–V) was assessed after immunostaining with anti-human alpha actin (1:800; Monosan, Uden, The Netherlands) for smooth

[43x224]HDL-C by ≏ trapib (10–300 mg) decreased LDL-C by ≏ pressure effect as observed with torcetrapib. In phase II trials, anacetrapib and evacetrapib have remarkable lipid-modulating abilities without the unwanted blood development. Among these, anacetrapib and evacetrapib have risk of major CV events and mortality despite a 72% increase in large clinical outcome trial (ILLUMINATE), torcetrapib increased the trial. Nonetheless, other CETP inhibitors are currently in clinical benefit and resulted in premature termination of the dal-OUTCOMES with a minimal reduction in LDL-C, but did not translate into clinical interventions, including LDL-C-lowering and HDL-C-raising. These mice respond in a human-like manner to lipid-modulating interventions, including LDL-C-lowering and HDL-C-raising drugs. See Supplementary material online for more detailed information on the background of the APOE*3Leiden.CETP mice and their response to hypolipidaemic drugs.
Anacetrapib reduces atherosclerosis via non-HDL-C

Statistical analyses
Significance of differences between the groups was calculated non-parametrically using a Kruskal–Wallis test for independent samples, followed by a Mann–Whitney U test for independent samples. An analysis of covariance (ANCOVA) was performed for test for group differences in a lesion area with HDL-C and non-HDL-C exposure as covariates. To test whether collinearity was present between the explanatory variables, we calculated the variance inflation factor (VIF) and the condition index (CI). Values of VIF >5 and values of CI >10 were used as a cutoff for collinearity.

SPSS 17.0 for Windows was used for statistical analysis. All groups were compared with the control group and the combination group was compared with the atorvastatin group. Bonferroni–Holm’s method was used to determine the level of significance in the case of multiple comparisons. Values are presented as means ± SD. P-values < 0.05 were considered statistically significant.

For the full descriptions of the used methods, please see the Supplementary material online.

Results

Anacetrapib, atorvastatin, and their combination decrease cholesteryl ester transfer protein activity despite an increase in cholesteryl ester transfer protein concentration
To assess the extent to which an ascending dose range of anacetrapib inhibits CETP, we measured CETP activity after 8 weeks of treatment and CETP concentration after 21 weeks of treatment (Table 1). Anacetrapib monotherapy (0.03; 0.3; 3 and 30 mg/kg/day) reduced CETP activity by −59 to −100% (P < 0.001) and increased plasma CETP concentration by +11% (NS) to +29% (P < 0.001). Both CETP activity and concentration were decreased by atorvastatin alone (−29 and −24%, P < 0.001) and in combination with 0.3 mg/kg/day anacetrapib (−84 and −23%, P < 0.001). Thus, adding anacetrapib to atorvastatin further reduced CETP activity (−78%, P < 0.001) without affecting CETP concentration when compared with atorvastatin.

Anacetrapib alone and in combination with atorvastatin reduces plasma non-HDL-cholesterol and increases HDL-cholesterol
During the study, plasma lipids were measured every 2–4 weeks and average plasma TC (Figure 1A), TG (Figure 1B), non-HDL-C (Figure 1C), and HDL-C (Figure 1D) were calculated. In the control group, the Western-type diet resulted in an average plasma TC of 10.8 ± 1.1 mmol/L, TG of 1.8 ± 0.5 mmol/L, non-HDL-C of 9.5 ± 1.1 mmol/L, and HDL-C of 1.2 ± 0.2 mmol/L. When compared with the control, anacetrapib monotherapy (0.03; 0.3; 3 and 30 mg/kg/day) decreased TC (−19; −25; −27, and −31%, P < 0.001 for all) mainly by decreasing non-HDL-C (−24; −36; −42, and −45%, P < 0.001 for all). In addition, anacetrapib monotherapy increased HDL-C (+30; +60; +86; and +86%, P < 0.001 for all) and decreased TG (−21%, P = 0.07; −22%, P = 0.06; −19%, NS and −27%, P < 0.01). Atorvastatin decreased TC (−33%, P < 0.001) by decreasing non-HDL-C (−37%, P < 0.001) and with no effect on HDL-C and TG. The combination treatment decreased TC (−48%, P < 0.001), non-HDL-C (−60%, P < 0.001) and TG (−33%, P < 0.01) and increased HDL-C (+56%, P < 0.001). Anacetrapib enhanced the lipid-modifying effects of atorvastatin with greater reductions in TC (−22%, P < 0.001), non-HDL-C (−36%, P < 0.001) and TG (−32%, P < 0.001) and a greater increase in HDL-C (+72%, P < 0.001) when comparing the combination treatment to atorvastatin monotherapy. Lipoprotein profiles confirmed the lipid-modifying effects of anacetrapib and revealed the formation of larger HDL particles, as observed previously after treatment with higher dosages of anacetrapib (3 and 30 mg/kg).

Table 1 Effect of anacetrapib, atorvastatin, and their combination on the cholesteryl ester transfer protein activity after 8 weeks of treatment and cholesteryl ester transfer protein concentration after 21 weeks of treatment

<table>
<thead>
<tr>
<th></th>
<th>Plasma CETP activity (nmol/mL/h)</th>
<th>Plasma CETP concentration (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>66.8 ± 10.1</td>
<td>15.7 ± 1.2</td>
</tr>
<tr>
<td>0.03 mg/kg/day anacetrapib</td>
<td>27.1 ± 7.1*** (−59%)</td>
<td>17.4 ± 3.1 (+11%)</td>
</tr>
<tr>
<td>0.3 mg/kg/day anacetrapib</td>
<td>6.3 ± 4.8*** (−91%)</td>
<td>19.9 ± 2.4*** (+27%)</td>
</tr>
<tr>
<td>3 mg/kg/day anacetrapib</td>
<td>0.7 ± 3.3*** (−99%)</td>
<td>20.2 ± 3.1*** (+29%)</td>
</tr>
<tr>
<td>30 mg/kg/day anacetrapib</td>
<td>0.0 ± 2.3*** (−100%)</td>
<td>18.5 ± 4.1 (+18%)</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>47.5 ± 8.2*** (−29%)</td>
<td>11.9 ± 2.3*** (−24%)</td>
</tr>
<tr>
<td>Atorvastatin + 0.3 mg/kg/day anacetrapib</td>
<td>10.5 ± 8.3*** (−84%)</td>
<td>12.1 ± 2.1*** (−23%)</td>
</tr>
</tbody>
</table>

**p < 0.001 when compared with control.
***p < 0.001 when compared with atorvastatin. Data are presented as means ± SD (% inhibition or increase when compared with the control); n = 15 per group.
Atorvastatin in combination with anacetrapib reduces atherosclerosis progression to a greater extent than atorvastatin alone

After 21 weeks of treatment, the effects of anacetrapib, atorvastatin and their combination on the progression of atherosclerosis were assessed in the aortic root area as illustrated by representative images in Figure 2. The number of lesions (Figure 3A), lesion area (Figure 3B), undiseased segments (Figure 3C), and lesion severity (Figure 3D) were assessed as previously described.28,29 For the control group, 4.1 ± 0.6 lesions per cross-section developed with a total lesion area of 169 ± 51 × 10^3 μm². Approximately 71% of these lesions were severe lesions (type IV–V) and only 5% of the segments were undiseased. Anacetrapib monotherapy (0.03; 0.3; 3; and 30 mg/kg/day) dose-dependently reduced the lesion area (−41%, P < 0.01; −72; −86; and −92%, P < 0.001 for all) and the number of lesions and improved lesion severity as indicated by less severe lesions (down to 15%, P < 0.001) and more undiseased segments (up to 46%, P < 0.001). Atorvastatin monotherapy reduced the total lesion area (−63%, P < 0.001) and improved lesion severity without affecting the number of lesions and undiseased segments. When compared with the control, the combination treatment further decreased the total lesion area (−95%, P < 0.001), the number of lesions (−41%, P < 0.01), and lesion severity and increased the percentage of undiseased segments.
Figure 2 Effect of anacetrapib, atorvastatin, and their combination on plaque morphology. Representative images of haematoxylin–phloxine–saffron-stained atherosclerotic lesions in a cross-section of the aortic root area for the control group (A), 0.03 mg/kg/day anacetrapib (B), 0.3 mg/kg/day anacetrapib (C), 3 mg/kg/day anacetrapib (D), 30 mg/kg/day anacetrapib (E), atorvastatin group (F), and the combination group (G) after 21 weeks of treatment.
When compared with atorvastatin monotreatment, the combination treatment decreased the total lesion area (−28.7%, \(P < 0.001\)), the number of lesions (−34%, \(P = 0.06\)) and severity and increased the percentage undiseased segments to a greater extent, indicative of an additional effect of anacetrapib on top of the statin.

**Anacetrapib, atorvastatin, and their combination improve lesion stability**

In addition to atherosclerotic lesion size and severity, we assessed the number of monocytes adhering to the endothelium as a functional marker for vascular inflammation (Figure 4A). Adhering monocytes per cross-section in the control group (i.e. 4.1 ± 2.6) were reduced by the higher dosages of anacetrapib (−60%, \(P < 0.01\) and −61%, \(P < 0.01\)), as well as by atorvastatin alone and in combination with anacetrapib (−48%, \(P < 0.05\) and −78%, \(P < 0.001\)). When compared with atorvastatin, the combination treatment reduced the number of monocytes to a greater extent (−57%, \(P < 0.01\)). In addition, we analysed the composition of the severe lesions (type IV–V), since these lesions are considered to be most vulnerable and prone to rupture. All parameters of lesion composition were calculated per cross-section as absolute values and as a percentage of the lesion area (see Supplementary material online). To this end, collagen content (Figure 4B) and SMC content in the cap (Figure 4C) were considered as stabilization factors, and macrophage content (Figure 4D) and necrotic content (Figure 4E) were considered as destabilization factors. The severe lesions in the control group consisted of ~54% collagen, 6% SMC in the cap, 10% macrophages and 4% necrosis. The lesion stability index for the control group presented as the ratio of stabilization to destabilization factors was 4.9 ± 2.0 (Figure 4F).

When corrected for the lesion area, the two higher dosages of anacetrapib (3 and 30 mg/kg/day) revealed a more stable plaque phenotype by increasing collagen content (+21%, \(P < 0.001\) and +28%, \(P < 0.001\); Figure 4B) and SMC content in the cap (+120%, \(P < 0.01\) and +119%, \(P < 0.05\)) and by decreasing macrophage (−53%, \(P = 0.06\) and −60%, \(P = 0.05\)) and necrotic (−73%, \(P < 0.001\) and −46%, \(P < 0.05\)) content. This is reflected by an increase in lesion stability index in these two treatment groups (+427%, \(P < 0.001\) and +366%, \(P < 0.01\)), Atorvastatin in combination with anacetrapib tended to increase the SMC content in the cap (+194%, \(P = 0.07\)) and decreased necrotic content (−96%, \(P < 0.05\)) with no effect on the lesion stability index. However, it should be noted that there were almost no lesions in the combination group and only two mice that received the combination treatment of anacetrapib and atorvastatin developed severe lesions.

**Anacetrapib does not affect HDL function**

To explore the contribution of the anacetrapib-induced increase in HDL-C to the reduction of atherosclerosis, we investigated the
endothelial-vasoprotective properties of HDL, in particular with respect to anti-inflammatory and anti-apoptotic properties in cultured arterial endothelial cells. HDL isolated from anacetrapib-treated mice had no effect on pro-inflammatory cytokine-induced VCAM-1 expression (Figure 5A) or on apoptotic cell death (Figure 5B).

Anacetrapib reduces atherosclerosis progression primarily by reducing non-HDL-cholesterol exposure

We evaluated whether the effects of anacetrapib and atorvastatin on atherosclerosis development could be explained by either an increase in HDL-C or a decrease in non-HDL-C or both. The lesion area was normalized by cubic root transformation (lesion area\(^{1/3}\)). Univariate regression analysis showed that the lesion area was predicted by TC (Figure 6A), mainly non-HDL-C (Figure 6B) and to a lesser extent by HDL-C (Figure 6C). Analysis of covariance showed that both anacetrapib treatment, at the dosages of 3 and 30 mg/kg/day (\(P < 0.05\)) and non-HDL-C (\(P < 0.001\)), but not HDL-C (\(P = 0.76\)), independently determined lesion size. Importantly, the variance inflation factors of HDL-C and non-HDL-C (VIF = 4.42 and 3.18, respectively) and the condition index (CI = 4.43) did not exceed the threshold for collinearity between the explanatory variables. Collectively, these data are compatible with a mechanism that anacetrapib mainly decreases atherosclerotic lesion development via a reduction of non-HDL-C with an additional effect by the compound itself at the higher doses (Figure 7).
Anacetrapib slightly increased serum amyloid A as a marker of inflammation

To assess the effect of anacetrapib on general inflammatory status, we measured plasma SAA levels, a systemic inflammatory marker after 16 weeks of treatment (Figure 8). Plasma SAA levels in the control group were $1.6 \pm 0.5 \mu g/mL$. When compared with the control, 0.3 mg/kg/day anacetrapib tended to increase SAA levels ($+37\%$, $P = 0.07$). No effects on body weight (gain) and food intake were noted with any of the treatments (data not shown).

Discussion

The present study is the first intervention study in a mouse model for atherosclerosis designed to investigate the effects of the CETP inhibitor anacetrapib alone and in combination with atorvastatin on the progression of atherosclerosis, lesion stability, and HDL function. In clinical trials, the effectiveness of novel treatment regimes in CVD is only being tested in patients on a statin background which makes this study unique in also evaluating the effects of anacetrapib monotreatment. In APOE*3Leiden.CETP mice, a broad dose range of anacetrapib dose-dependently reduced atherosclerosis development. This effect was mainly ascribed to the reduction in non-HDL-C despite a remarkable increase in HDL-C and without affecting HDL functionality. Anacetrapib improved lesion stability when given at a higher dose (3 and 30 mg/kg/day). In addition, a moderate dose of anacetrapib (0.3 mg/kg/day) added to the anti-atherogenic effects of atorvastatin.

In our study, incremental dosages of 0.03–30 mg/kg/day anacetrapib dose-dependently decreased CETP activity by $>60\%$, decreased non-HDL-C by $24–45\%$ and increased HDL-C by $30–86\%$. These lipid-altering effects are comparable with findings from phase I, II and III clinical trials. In phase I trials, an anacetrapib-induced reduction in CETP activity of $>60\%$ was accompanied by dose-dependent LDL-C-lowering and HDL-C-raising effects both in healthy subjects and in patients with dyslipidaemia. In line with our results, these studies also report an increase in CETP concentration possibly...
due to the formation of an inactive complex between CETP and HDL.\textsuperscript{34} In a phase II trial, 8 weeks of treatment with ascending dosages of anacetrapib monotherapy (10–300 mg/day) reduced LDL-C by 16–39% and increased HDL-C by 44–139%. Similar to our study, the addition of anacetrapib to atorvastatin produced incremental LDL-C reductions.\textsuperscript{23} The higher dosages of anacetrapib (3 and 30 mg/kg/day) also revealed an effect on atherosclerosis that was independent of non-HDL-C, but this effect was not explained by the increase in HDL-C.

Inconsistent data have been reported on the effect of other CETP inhibitors on atherosclerosis development in animals expressing CETP. In rabbits, dalcetrapib reduced atherosclerosis in one study with no effect in another study.\textsuperscript{15,17} In contrast to the human situation,\textsuperscript{21} the reduction in atherosclerosis after dalcetrapib treatment was accompanied by a 40–50% decrease in non-HDL-C together with an increase in HDL-C.\textsuperscript{15} In mice, torcetrapib monotherapy decreased atherosclerosis.\textsuperscript{19} However, unlike the present study, these effects were not enhanced in combination with atorvastatin in the same mouse model.\textsuperscript{19} In rabbits, torcetrapib treatment decreased atherosclerosis where the aortic lesion area correlated with the TC/HDL-C ratio.\textsuperscript{18} This could suggest a possible anti-atherogenic role of increased HDL-C or other pleiotropic effects of HDL. However, in the APOE*3Leiden.CETP mouse model, statistical analyses revealed that HDL-C was not an independent predictor of the lesion area when non-HDL-C was included as covariate, suggesting that the effect of anacetrapib on atherosclerosis development was mainly mediated through the reduction of non-HDL-C. The higher dosages of anacetrapib (3 and 30 mg/kg/day) also revealed an effect on atherosclerosis that was independent of non-HDL-C, but this effect was not explained by the increase in HDL-C.

Besides atherosclerotic lesion size, lesion composition should also be taken into consideration given that in the human situation, a vulnerable lesion consisting of more macrophages, a large necrotic core and a thin, collagen-poor, fibrous cap is more prone to rupture.\textsuperscript{35} Previously, our group showed that torcetrapib produced a pro-inflammatory, unstable plaque phenotype as seen by increased monocyte adherence to the vascular endothelium and consequently increased macrophage content of the lesions.\textsuperscript{19} In the present study, anacetrapib decreased monocyte adherence and improved lesion

\textbf{Figure 7} Hypothetical scheme of factors contributing to the effect of anacetrapib on the atherosclerotic lesion area as suggested by statistical analyses. An analysis of covariance was performed to test for group differences in the lesion area with HDL-C and non-HDL-C exposure as covariates. HDL-C was not an independent predictor of the lesion area when non-HDL-C was included as covariate, suggesting that the effect of anacetrapib on atherosclerosis development was mainly mediated through the reduction of non-HDL-C. The higher dosages of anacetrapib (3 and 30 mg/kg/day) also revealed an effect on atherosclerosis that was independent of non-HDL-C, but this effect was not explained by the increase in HDL-C.

\textbf{Figure 8} The effects of anacetrapib, atorvastatin, and their combination on plasma SAA levels were measured after 16 weeks of treatment. *P < 0.05 when compared with control. Data are presented as means ± SD (n = 15 per group).
composition as shown by an increase in stabilization factors (collagen and SMC content) and a decrease in destabilization factors (macrophage and necrotic content). The inconsistencies can be ascribed to the off-target activation of the renin–angiotensin–aldosterone system (RAAS) and blood pressure effect of torcetrapib. Indeed, in our mouse model for atherosclerosis, torcetrapib also increased aldosterone levels in plasma.

The large phase III DEFINE trial was designed to further assess the efficacy and tolerability of anacetrapib in statin-treated patients with or at risk for coronary heart disease. Anacetrapib (100 mg/day) decreased LDL-C by 40% and increased HDL-C by 138% with an acceptable safety profile and no indication for an increase in CV events. In fact, post hoc analyses suggested a reduction in CV end-points. These initial data provided a rationale for conducting a larger clinical end-point trial of pharmacological CETP inhibition despite the conflicting outcomes of genetic CETP deficiency and the ILLUMINATE trial. In view of the detrimental effects of torcetrapib in the ILLUMINATE trial, anacetrapib was thoroughly screened and revealed minimal side-effects without any indication for an off-target pressure effect.

Despite the absence of reported side-effects of anacetrapib, there are some concerns about target-related side-effects due to formation of large buoyant cholesterol-rich HDL-2 particles after CETP inhibition, which may be dysfunctional with regard to their endothelial-vasoprotective effects and consequently their atheroprotective properties and that this may have contributed to the failure of torcetrapib. In the present study, we investigated the effects of HDL isolated from control and anacetrapib-treated mice on parameters of vascular inflammation and function. HDL from anacetrapib-treated mice did not suppress cytokine-induced adhesion molecule expression or cell apoptosis in endothelial cells. This is in line with results from recent studies where no differences were observed in the effect of HDL from control or anacetrapib-treated hamsters and humans on inflammatory markers (adhesion molecule expression, monocyte chemotactic protein-1 secretion, monocyte adhesion, NFkB activation, and cytokine mRNAs) in endothelial cells and macrophages. Importantly, although anacetrapib treatment did not improve the anti-inflammatory and anti-apoptotic effects of HDL, it also did not adversely affect these functions of HDL. In addition, we found no effect of anacetrapib on serum paraoxonase 1 activity and the aortic content of reactive oxygen species (data not shown). Formation of large cholesterol-rich HDL-2 particles in CETP-deficiency or after CETP inhibition has also been suggested to affect the cholesterol efflux capacity of these particles. Although we did not address this in the present study, data from literature consistently indicate that the cholesterol efflux capacity is not impaired but improved. HDL from CETP-deficient patients displayed enhanced ability to promote cholesterol efflux from macrophages in a ABCG1-dependent manner. In humans, anacetrapib-treated HDL showed increased ABCA1- and ABCG1-mediated cholesterol efflux capacity. Collectively, these data indicate that CETP inhibition does not result in formation of dysfunctional HDL with regard to its atheroprotective properties as assessed by ex vivo (cell) assays.

This effect was alleviated when anacetrapib was given in combination with atorvastatin.

The effects of two other CETP inhibitors, DRL-17822 and TA-8995 (DEZ-001), as well as a vaccine against CETP, ATH03, are being tested in phase II clinical development. In large phase III clinical trials, the effects of 100 mg anacetrapib (REVEAL) and 130 mg evacetrapib (ACCELERATE) in patients on standard statin treatment on CV outcomes are currently being investigated and results are expected in 2016–17. The outcome of these trials will resolve the unanswered questions regarding possible beneficial effects of pharmacological CETP inhibition and may give additional insight into the HDL-hypothesis and the contribution of HDL and non-HDL to CV end-points.

Supplementary material

Supplementary material is available at European Heart Journal online.

Acknowledgement

We would like to thank Erik Offerman (TNO), Wen Liang (TNO/LUMC) and Jasmin Manz (University of Zurich) for their excellent technical assistance.

Funding

This research was performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project PREDici (KOVWD, grant O1C-104), and supported by the Dutch Heart Foundation, Dutch Diabetes Research Foundation and Dutch Kidney Foundation and Netherlands Consortium for Systems Biology. We acknowledge the support from ‘the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences’ for the GENIUS project ‘Generating the best evidence-based pharmaceutical targets for atherosclerosis’ (CVON2011-19). PCNR is an Established Investigator of the Netherlands Heart Foundation (20091038). Funding to pay the Open Access publication charges for this article was provided by TNO (Netherlands Organization for Applied Scientific Research TNO).

Conflict of interest: J.W.J. received research grants from and was speaker on (CME accredited) meetings sponsored by Amgen, Astellas, Astra-Zeneca, Biotronik, Boston Scientific, Daiichi Sankyo, Lilly, Genzyme, Medtronic, Merck-Schering-Plough, Pfizer, Orbis Neich, Novartis, Roche, Servier, Sanofi Aventis, the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands and the European Community Framework KTP Programme.

References


